

Anne Whitney Brown, MD

Transplant Pulmonologist
Inova Advanced Lung Disease and Transplant Program
3300 Gallows Road
Falls Church, VA 22042
(703) 300-0217
anne.brown@inova.org

EDUCATION

Emory University , Atlanta, GA Doctor of Medicine	1999-2003
University of North Carolina at Chapel Hill Bachelor of Science in Public Health	1995-1999

MEDICAL TRAINING

University of North Carolina Hospitals , Chapel Hill, NC Pulmonary and Critical Care Fellowship	2006-2009
New York Presbyterian Hospital-Cornell , New York, NY Internal Medicine Residency	2003-2006

CERTIFICATIONS / LICENSURE

American Board of Internal Medicine: Critical Care Certification	2019, 2009
American Board of Internal Medicine: Pulmonary Disease Certification	2018, 2008
American Board of Internal Medicine: Internal Medicine Certification	2006
Virginia Medical Board Licensure	2010-active
North Carolina Medical Board Licensure	2006
New York Medical Board Licensure	2005

POSITIONS

Cystic Fibrosis Foundation , Bethesda, MD Senior Director, Clinical Affairs (0.8 FTE)	July 2021-current
Inova Fairfax Advanced Lung Disease and Transplant Program , Falls Church, VA Center Director, Cystic Fibrosis Center at Inova Director, Adult Cystic Fibrosis and Bronchiectasis Program Director, Clinical Operations Transplant Pulmonologist (part-time capacity since July 2021)	2017-2021 2010-2021 2015-2019 2010-current
University of North Carolina , Chapel Hill, NC Clinical Instructor, Division of Pulmonary and Critical Care Medicine	July 2009-July 2010

ACADEMIC APPOINTMENTS

Associate Professor of Medical Education Department of Medicine University of Virginia School of Medicine	August 2020-current
Associate Professor of Medicine Assistant Professor	June 2018-current June 2011-May 2018

Department of Medicine
Virginia Commonwealth University School of Medicine

PROFESSIONAL AND SOCIETY MEMBERSHIPS

Member, American Thoracic Society
Member, International Society of Heart and Lung Transplantation

RESEARCH INTERESTS

Clinical Outcomes in Cystic Fibrosis, Lung Transplantation, Idiopathic Pulmonary Fibrosis

RESEARCH EXPERIENCE

Clinical Research:

Inova Advanced Lung Disease Program, Co-Director of Research 2015-2020

University of North Carolina, Chapel Hill, NC

Mentored Patient-Oriented Research Career Development (K23) Program 2009-2010

Mucociliary Clearance (MCC) in Cystic Fibrosis Lung Disease 2008-2010

Basic Science Research:

University of North Carolina, Chapel Hill, NC

Pathogenesis of Viral Infections in Chronic Lung Disease 2007-2008

Fellow, Division of Pulmonary and Critical Care

Weill Cornell Medical College, New York, NY 2005-2006

Medical resident, Molecular Cardiology Laboratory

Emory University School of Medicine, Atlanta, GA

Medical student, Department of Pathology 2002-2003

Undergraduate summer research student, Department of Pathology 1997

University of North Carolina, Chapel Hill, NC 1997-1999

Undergraduate student, Department of Nutrition

TEACHING EXPERIENCE

Inova Fairfax Advanced Lung Disease & Transplant Program 2010-current

- Involved in medical student, resident, and fellowship training

Associate Professor University of Virginia-Inova 2020-current

Associate Professor VCU-Inova 2018-2020

Assistant Professor VCU-Inova 2011-2018

University of North Carolina, Chapel Hill, NC 2009-2010

Clinical Instructor, Division of Pulmonary and Critical Care Medicine

New York Presbyterian Hospital-Cornell Internal Medicine Residency 2005-2006

Assistant Chief Resident

Emory University School of Medicine 2002-2003

Problem Based Learning (PBL) Facilitator

SCHOLARSHIP

Scientific Reviewer, *Annals of the American Thoracic Society*
Scientific Reviewer, *Thorax*
Scientific Reviewer, *Chest*
Scientific Reviewer, *Journal of Heart and Lung Transplantation*
Scientific Reviewer, *European Respiratory Journal*
Scientific Reviewer, *Progress in Transplantation*
Scientific Reviewer, *Respiratory Medicine*
Scientific Reviewer, *Journal of Evaluation in Clinical Practice*
Scientific Reviewer, *British Medical Journal Open Quality*
Scientific Reviewer, *Transplant International*
Scientific Reviewer, *Open Forum Infectious Diseases*
Scientific Reviewer, *Journal of Cystic Fibrosis*
Scientific Reviewer, *Annals of Palliative Medicine*
Steering Committee Member and Faculty

PILOT for IPF Educational Program, The France Foundation 2014-2019

SERVICE/LEADERSHIP

Organ Procurement and Transplantation Network/United Network for Organ Sharing
(OPTN/UNOS) **Lung Review Board, Member** 2023-2025

OPTN/UNOS **Peer Mentoring Program, Mentor** 2022

Organ Procurement and Transplantation Network/United Network for Organ Sharing
(OPTN/UNOS) **Lung Transplantation Committee, Region 2 Representative** 2020-2022

OPTN/UNOS **Thoracic Organ Transplantation Committee, Region 2 Representative** 2019-2020

OPTN/UNOS **Peer Review Panel Member** 2017

Inova Heart and Vascular Institute **Physician Leadership Training Program Participant** 2016-2017

HONORS / AWARDS

2009 Philip A. Bromberg Chief's Award for Excellence in Research
Assistant Chief Resident 2005-2006, New York Presbyterian Hospital-Cornell
Magna Cum Laude
Alpha Omega Alpha
2003 Janet M. Glasgow Achievement Citation
Phi Beta Kappa
Highest Honors for Undergraduate Thesis
Department of Nutrition Undergraduate Award for Outstanding Research
Delta Omega Public Health Society Undergraduate Award for Excellence

PUBLICATIONS

Original Research Papers

1. Ostrenga JS, **Brown AW**, Todd JV, Elbert A, Fink AK, Faro A, Marshall BC, Cromwell EA. Impact of loss to follow-up on survival estimation for cystic fibrosis. Submitted to Clinical Epidemiology, February 2023.
2. Cromwell, E. **Brown AW**. Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020, accepted J Cyst Fibros, February 2023.
3. Mallea JM, Hartwig MG, Keller CA, Kon Z, Pierson RN, Erasmus DB, Roberts M, Patzlaff NE, Johnson D, Sanchez PG, D’Cunha J, **Brown AW**, Dilling DF, McCurry K. Remote ex vivo lung perfusion at a centralized evaluation facility, J Heart Lung Transplantation 2022, doi: <https://doi.org/10.1016/j.healun.2022.09.006>
4. Dedrick RM, Smith BE, Cristinziano M, Freeman KG, Jacobs-Sera D, Belessis Y, **Brown AW**, Cohen KA, Davidson RM, van Duin D, Gainey A, Garcia CB, Robert George CR, Haidar G, Ip W, Iredell J, Khatami A, Little JS, Malmivaara K, McMullan BJ, Michalik DE, Moscatelli A, Nick JA, Tupayachi Ortiz MG, Polenakovik HM, Robinson PD, Skurnik M, Solomon DA, Soothill J, Spencer H, Wark P, Worth A, Schooley RT, Benson CA, Hatfull GF. Phage Therapy of Mycobacterium Infections: Compassionate-use of Phages in Twenty Patients with Drug-Resistant Mycobacterial Disease. Clin Infect Dis. 2022 Jun 9:ciac453. doi: 10.1093/cid/ciac453. Epub ahead of print. PMID: 35676823.
5. Raghu G, Hamblin MJ, **Brown AW**, Golden JA, Ho LA, Wijisenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Burgess T, Kamath N, Donaldson F, Richeldi L. Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study Respir Res 2022 May 21;23(1):129. doi: 10.1186/s12931-022-02047-0.
6. Bazemore K, Rohly M, Permpalung N, Yu K, Timofte I, **Brown AW**, Orens J, Iacono A, Nathan SD, Avery RK, Valentine H, Agbor-Enoh S, Shah PD. Donor derived cell free DNA% is elevated with pathogens that are risk factors for acute and chronic lung allograft injury. J Heart Lung Transplant 2021;40(11):1454-1462.
7. Strich JR, Tian X, Samour M, King CS, Shlobin O, Reger R, Cohen J, Ahmad K, **Brown AW**, Khangoora V, Aryal S, Migdady Y, Kyte JJ, Joo J, Hays R, Collins AC, Battle E, Valdez J, Rivero J, Kim IK, Erb-Alvarez J, Shalhoub R, Chakraborty M, Wong S, Colton B, Ramos-Benitez MJ, Warner S, Chertow DS, Olivier KN, Aue G, Davey RT, Suffredini AF, Childs RW, Nathan SD. Fostamatinib for the treatment of hospitalized adults with COVID-19 A randomized trial. Clin Infect Dis; 2021 Sep 01.
8. King CS, Freiheit E, **Brown AW**, Shlobin OA, Aryal S, Ahmad K, Khangoora V, Flaherty KR, Venuto D, Nathan SD. Association Between Anticoagulation and Survival in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Patient Registry. Chest 2021; 159(4):1507-1516.
9. Pastre J, Barnett SD, Ksovreli I, Mogulkoc N, Ramalingam V, Fukuda C, Yelisetty A, Selim Unat O, **Brown AW**, Shlobin OA, Ahmad K, Khangoora V, Aryal S, King C, Nathan SD.

Development and Validation of a Clinical Diagnostic Scoring System for the Diagnosis of IPF. *Ann Am Thorac*; 12 Apr 2021,DOI: 10.1513/annalsats.202011-1430oc.

10. Chandel A, Verster A, Rahim H, Khangoora V, Nathan SD, Ahmad K, Aryal S, Bagnola A, Singhal A, **Brown AW**, Shlobin OA, King CS. EXPRESS: Incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension. *Pulm Circ*. 2021 April 28; 11;11(2):20458940211012366. doi: 10.1177/20458940211012366.
11. Nunes FS, Pastre J, **Brown AW**, Shlobin OA, King CS, Weir NA, Nathan SD. Does 1-minute walk test predict results of 6-minute walk test in patients with idiopathic pulmonary fibrosis? *Sarcoidosis Vasc Diffuse Lung Dis* 2021; 38 (1); e2020026. doi: 10.36141/svldd.v38i1.9258.
12. Pastre J, Khandhar S, Barnett S, Ksovreli I, Mani H, **Brown AW**, Shlobin OA, Ahmad K, Khangoora V, Aryal S, Morris DL, King CS, Nathan SD. Surgical lung biopsy for interstitial lung disease: safety and feasibility at a tertiary referral center. *Ann Am Thorac Soc* 2021;18(3):460-467.
13. Keller M, Bush E, Diamond JM, Shah PD, Matthews J, **Brown AW**, Sun J, Timofte I, Kong H, Tunc I, Luikart H, Iacono A, Nathan SD, Khush KK, Orens JB, Jang M, Valantine HA, Agbor-Enoh S. Use of Donor-Derived-Cell-Free DNA as a Marker of Early Allograft Injury in Primary Graft Dysfunction to Predict the Risk of Chronic Lung Allograft Dysfunction (CLAD). *Remote ex vivo lung perfusion at a centralized evaluation facility* 2021;40(6):488-493.
14. Agbor-Enoh S, Tunc I, Berry GJ, Marboe C, Jang MK, Kong H, Shah PD, **Brown AW**, Ponor IL, Fideli U, Marishta A, Bhatti K, Mutebi C, Gorham S, Yang Y, Philogene1 MC, Yu K, Iacono A, Orens JB, Nathan SD, Valantine HA. Donor-derived cell-free DNA Accurately Detects Acute Rejection in Lung Transplant Patients, A Multicenter Cohort Study. *J Heart Lung Transplant*. 2021;40(8):822-830.
15. King CS, Sahjwani D, **Brown AW**, Feroz S, Cameron P, Osborn E, Desai M, Djurkovic S, Kasarabada A, Hinerman R, Lantry J, Speir A, Shlobin OA, Ahmad K, Khangoora V, Aryal S, Collins AC, Nathan SD. Outcomes of Mechanically Ventilated Patients with COVID-19 Associated Respiratory Failure. *PLoS One*. 2020; 15(11):e0242651.
16. Nathan SD, **Brown AW**, Mogulkoc N, Soares F, Collins AC, Cheng JM, Peterson J, Cannon B, Barnett SD. The White Blood Cell Count as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis. *Respiratory Medicine* 2020; 170:106068. <https://doi.org/10.1016/j.rmed.2020.106068>.
17. Ratwani AP, Ahmad KI, Barnett SD, Nathan SD, **Brown AW**. Connective tissue disease-associated interstitial lung disease and outcomes after hospitalization: A cohort study. *Respiratory Medicine* 2019; 154:1-5.
18. Raghu G, van den Blink B, Hamblin MJ, **Brown AW**, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Moran D, Santin-Janin H, Aubin F, Mulder G-J, Gupta R, Richeldi L. Long-term Recombinant Human Pentraxin-2 in Patients with Idiopathic Pulmonary Fibrosis. *Lancet Respiratory Medicine* 2019; 7(8):657-664.
19. Rahaghi FF, Safdar Z, **Brown AW**, de Andrade JA, Flaherty KR, Kaner RJ, King CK, Padilla ML, Noth I, Scholand MB, Shifren A, Nathan SD. Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking

pirfenidone for idiopathic pulmonary fibrosis: A Delphi consensus study. *BMC Pulm Med* 2020; 20:191 <https://doi.org/10.1186/s12890-020-01209-4>.

20. Valentine H, Agbor-Enoh S, Wang Y, Tunc I, Kyoo Jang M, Davis A, De Vlaminc I, Luikart H, Shah PD, Timofte I, **Brown AW**, Marishta A, Bhatti K, Gorham S, Fideli U, Wylie J, Goodwin N, Yang Y, Patel K, Zhu J, Iacono A, Orens JB, Nathan SD, Marboe C, Berry GJ, Quake SR, Khush K. Donor-derived Cell-free DNA Predicts Allograft Failure and Mortality after Lung Transplantation. *EBioMedicine*, <https://doi.org/10.1016/j.ebiom.2018.12.029>.
21. King CK, **Brown AW**, Ahmad S, Shlobin OA, Weir N, Libre M, Franco-Palacios D, Nathan SD. Prevalence and Impact of Group 3 Pulmonary Hypertension in Idiopathic Nonspecific Interstitial Pneumonia. *Eur Respir J* 2018; 52: 1800545.
22. Raghu G, van den Blink B, Hamblin MJ, **Brown AW**, Golden JA, Ho LA, Wijssenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer K, Kreuter M, Santin-Janin H, Mulder G-J, Bartholmai B, Gupta R, Richeldi L. Recombinant Human Pentraxin-2 in Patients with Idiopathic Pulmonary Fibrosis. *JAMA* 2018; 319 (22):2299-2307.
23. Trimble A, **Brown AW**, Laube B, Lechtzin, N, Zeman K, Wu J, Ceppe A, Waltz D, Bennett W, Donaldson S. Hypertonic Saline Has A Prolonged Effect On Mucociliary Clearance In Adults With Cystic Fibrosis. *J Cyst Fibros* 2018; doi.org/10.1016/j.jcf.2018.01.001.
24. Agbor-Enoh S, Jackson AM, Tunc I, Berry GJ, Cochrane A, Grimm D, Davis A, Shah P, **Brown AW**, Wang Y, Timofte I, Shah P, Gorham S, Wylie J, Goodwin N, Jang MK, Marishta A, Bhatti K, Fideli U, Yang Y, Luikart H, Pirooznia M, Zhu J, Iacono A, Nathan SD, Orens J, Khush K, Valentine H. Clinical pulmonary antibody-mediated rejection (AMR) is a late manifestation of allo-antibody-associated injury. *J Heart Lung Transpl* 2018; 37(7):925-932.
25. Jose A, King CS, Shlobin OA, Kiernan J, Cossa N, **Brown AW**, Nathan SD. Ventricular diastolic pressure ratio as a marker of treatment response in pulmonary hypertension. *Chest* 2017; 152(5): 980-989.
26. King CS, Shlobin OA, **Brown AW**, Nathan SD. Early Post-Operative Management After Lung Transplantation: Results of an International Survey. *Clinical Transplantation*. 2017; 31:e12985.
27. Hong A, King CS, **Brown AW**, Ahmad S, Shlobin OA, Khandhar S, Bogar L, Burton N, Rongione A, Nathan SD. Hemothorax Following Lung Transplantation: Incidence, Risk Factors, and Effect on Morbidity and Mortality. *Multidisciplinary Respiratory Medicine* 2016; 11:40-49.
28. Shin S, King CS, Puri N, Shlobin OA, **Brown AW**, Ahmad S, Weir N, Nathan SD. Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. *Eur Respir J* 2016; 47: 1445-1451.
29. **Brown AW**, Fischer CP, Shlobin OA, Buhr RG, Ahmad S, Weir NA, Nathan SD. Outcomes after Hospitalization in Idiopathic Pulmonary Fibrosis: a cohort study. *Chest* 2015;147(1):173-179.
30. Shin S, King CS, **Brown AW**, Albano MC, Atkins M, Sheridan M, Ahmad S, Newton K, Weir N, Shlobin OA, Nathan SD. Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease. *Respiratory Medicine* 2014;108(11):1626-32.

31. Weir NA, **Brown AW**, Shlobin OA, Smith MA, Reffett T, Battle E, Ahmad S, Nathan SD. The Influence of Alternative Instruction on the Six Minute Walk Test Distance. *Chest* 2013; 144(6):1900-1905.
32. Nathan SD, Reffett T, **Brown AW**, Fischer CP, Shlobin OA, Ahmad S, Weir N, Sheridan MJ. The Red Cell Distribution Width as a Prognostic Indicator in IPF. *Chest* 2013; 143:1692-98.
33. **Brown AW**, Shlobin OA, Weir N, Albano MC, Ahmad S, Smith M, Leslie K, Nathan SD. Dynamic Patient Counseling: A Novel Concept in IPF. *Chest* 2012; 142(4):1005-1010.
34. Shlobin OA, Weir N, **Brown AW**, Ahmad S, Brown K, Lemma M, Nathan SD. Transition of Pulmonary Hypertension Patients from Sildenafil to Tadalafil: Feasibility and Practical Considerations. *Lung*. 2012; 190(5):573-8.
35. Deng, J, Hua K, Lesser SS, Greiner AH, **Walter AW**, Marrero B, Harp JB. Interleukin-4mediates STAT-6 activation in 3T3-L1 preadipocytes but not adipocytes. *Biochemistry and Biophysics Research Communications*. Jan 2000; 267(2):516-520.

Reviews

1. Ahmad K, Pluhacek JL, **Brown AW**. Ex Vivo Lung Perfusion: A Review of Current and Future Application in Lung Transplantation. *Pulm Ther*. 2022 Mar 22. doi: 10.1007/s41030-022-00185-w. Epub ahead of print. PMID: 35316525.
2. Ratwani A, Gupta B, Stephenson BW, Mani H, **Brown AW**. The Spectrum of Drug-Induced Interstitial Lung Disease. *Current Pulmonology Reports*, 2019; 8:139-150.
3. King CS, **Brown AW**, Aryal S, Ahmad K, Donaldson S. Critical Care of the Adult Cystic Fibrosis Patient. *Chest* 2019; 155(1): 202–214.
4. **Brown AW** and Nathan SD. The Value and Application of the Six Minute Walk Test in Idiopathic Pulmonary Fibrosis. *Ann Am Thorac Soc* 2018; 15(1):3-10.
5. Shlobin OA, **Brown AW**, Nathan SD. Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases. *Chest* 2017;151(1):204-214.
6. **Brown AW**, Hatice K, Nathan SD. Lung Transplantation in Idiopathic Interstitial Pneumonia: A Review. *Respirology* 2016; 21(7): 1173–1184.
7. Hostler J, **Brown AW**, Sherner J, King CS, Nathan SD. Pulmonary Hypertension in COPD: A Review. *Eur Respir Monograph* 2013;59:189-205

Case Reports

1. Piechowiak, M, Aryal, S, **Brown AW**, Katugaha, S. Lung nodules due to *Candida parapsilosis* in a person with cystic fibrosis. Accepted to *BMJ*, December 2021.
2. Mabe D, Shlobin OA, Bogar, L, Nathan SD, **Brown AW**, Ahmad K, Aryal S, Murphy C, King CS. ECMO as a Bridge to Initial Medical Therapy in a Patient with Decompensated Pulmonary Arterial Hypertension. *Journal of Medical Cases* 2019: 10.
3. King C, Clement S, Katugaha S, **Brown AW**. Fungal Thyroiditis in a Lung Transplant Recipient. *BMJ Case Rep* 2018. doi:10.1136/bcr-2018-227033.
4. Warren W, Franco-Palacios D, King CS, Shlobin OA, Nathan SD, Katugaha S, Mani H, **Brown AW**. A 24-year-old woman with Precipitous Respiratory Failure after Lung Transplantation. *Chest* 2018; 153(3): e53–e56.

Editorial

1. **Brown AW**. Unclassifiable Interstitial Lung Disease: Time to Shrink the Black Box. *Annals ATS* 2018; 15(7):806–807.

Letters

1. Nathan SD, **Brown AW**, Weir N. Response to letter Six minute walk distance-effect of instructions. *Chest* 2014;145:1440-1441

Book Chapters/Books

1. **Brown AW**, Marshall BC. Organisation of Cystic Fibrosis Centre Care. In Hodson and Geddes' Cystic Fibrosis, 5th Edition. Bush A, Margarida D. Amaral MD, Davies JC, Simmonds NJ, Taylor-Cousar JL, Ranganathan S.(Eds.) (in progress 2022).
2. Nathan SD, **Brown AW**, King C. Guide to Clinical Management of Idiopathic Pulmonary Fibrosis. 2016.
3. **Brown AW**, Nathan SD. Making a Confident Diagnosis of Obliterative Bronchiolitis. Bronchiolitis Obliterans Syndrome in Lung Transplantation Series: Respiratory Medicine, Vol. 8. Meyer, Keith C.; Glanville, Allan R. (Eds.) 2013.
4. **Brown AW**, Donaldson SH. Mucus Abnormalities and Ciliary Dysfunction. In: Allen J, Panitch H, Rubenstein R, ed. Cystic Fibrosis. New York: Informa Healthcare Publications, 2010.

Curriculum Development

Indiana University School of Medicine Cystic Fibrosis Educational Courses: Course Six, Trimble A, **Brown AW**, Module 2: Advanced CF Lung Disease in the Critical Care Setting, Advanced Cystic Fibrosis Lung Disease & Lung Transplant, July, 2022. <https://medicine.iu.edu/cme/specialized/Cystic-Fibrosis>.

Abstracts

1. Utilization and Outcomes with Single Lung Transplantation Following Ex Vivo Lung Perfusion Using a Centralized Lung Evaluation System at a Dedicated Facility. Submitted to ISHLT 2023.
2. King CS, Saini J, Khangoora V, Aryal S, Singhal A, Nyquist AS, Ahmad K, **Brown AW**, Kennedy J, Psotka M, Nathan SD, Shlobin OA. Long-Term Follow-up of Pulmonary Arterial Hypertension Patients Managed with Oral Treprostinil. ATS 2022.
3. King CS, Ignacio RV, Freheit E, Aryal S, Khangoora V, Singhal AL, Nyquist A, **Brown AW**, Shlobin OA, Flaherty KR, Nathan SD. Hospitalization Rates in Various Interstitial Lung Diseases: An Analysis of the Pulmonary Fibrosis Foundation Registry. ATS 2022.
4. Extended Cold Preservation Times Are Not Associated with Increased Post-Transplant Mortality After Ex Vivo Lung Perfusion (EVLP) at a Dedicated Facility Using a Centralized Lung Evaluation System (CLES). ISHLT 2022.
5. Increasing Lung Transplant Availability with Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated Facility and a Centralized Lung Evaluation System (CLES): 3-Year Outcomes. ISHLT 2022.
6. Nyquist A, Khangoora V, Shlobin OA, Aryal S, King CS, Singhal A, Ahmad K, **Brown AW**, Nathan SD. Transplantation of Occult Signet Ring Cell Carcinoma Mimicking Pulmonary Venous-occlusive Disease. ISHLT 2022.
7. Singhal A, Duong Q, Bowen MA, King CS, **Brown AW**, Ahmad K. Glycemic Response to Exercise in Patients with Cystic Fibrosis Related Diabetes. NACFC 2021.
8. Prasanna D, **Brown AW**, Chakravorty S, Nathan SD, Aryal S. Incidence and Impact of Post-operative Acute Kidney Injury requiring renal replacement therapy during Index Lung Transplant Hospitalization. CHEST 2021.
9. Abhimanyu Chandel, Saloni Patolia, **Brown AW**, A. Claire Collins, Dhvani Sahjwani, Vikramjit Khangoora, Paula C. Cameron, Mehul Desai, Steven D. Nathan, Christopher S. King, Inhaled nitric oxide via high-flow nasal cannula in patients with acute respiratory failure related to COVID-19. CHEST 2021.
10. Jean Pastré; Solène Valéry; **Brown AW**; Oksana A. Shlobin; Kareem Ahmad; Vikramjit Khangoora; Shambhu Aryal; Christopher S. King; Nathan SD. Nathan. Idiopathic pulmonary fibrosis prognostic evaluation: could we do better? CHEST 2021.
11. Severe thrombocytopenia due to IV epoprostenol: Don't muck with the platelets. Ahmad Q, Singhal A, Khangoora V, Nathan SD, Aryal S, Ahmad K, **Brown AW**, Bagnola A, King C, Shlobin OA. CHEST 2021.
12. Gibson K, **Brown AW**, Lopynski E; Davies-Wellborn E, King C, Kahr M, Phillips Morrison ML, Riedy C, Standley J, Bush G, Blake S. Patient-centered Care of Hospitalized Adults with Cystic Fibrosis – a Collaboration Between the CF Care Team and the Patient Family Advisory Board. NACFC 2020.
1. Phillips Morrison ML, Riedy C, Kahr M, Jonathan Standley J, Davies-Wellborn E, Gibson K, **Brown AW**. Patient and Family Advisory Board (PFAB) Driven Clinical and Patient Driven Education. NACFC 2020.

2. Bowen MA; Alemayehu M; Battle E; **Brown, AW**. Promising Results with Elexacaftor/Ivacaftor/Tezacaftor Use in Cystic Fibrosis Patients with Advanced Lung Disease: Beyond the Clinical Trial Inclusion Criteria. ATS 2020.
3. Marinak L, Ahmad K, Peterson J, King CS, Katugaha S, Mahajan A, **Brown AW**. Endobronchial Valves for Persistent Bronchopleural Fistula after Pneumothorax in Cystic Fibrosis: A Double Edged Sword. ATS 2020.
4. Koslow M, Albano MC, Barnett SD, Ahmad K, **Brown AW**, Aryal S, King CS, Shlobin OA, Culotta B, Nathan SD. Non-Traumatic Vertebral Fractures are Associated with Decreased Survival in Lung Transplant Recipients. Accepted to ATS 2020 (poster discussion).
5. Pastre J, Ksovresli I, Taylor J, King CS, Vik K, Shlobin OA; **Brown AW**; Ahmad K; Aryal S; Nathan SD. Antifibrotic therapy in IPF patients with severe physiologic impairment. ATS 2020.
6. Pastre J, Inga K, Taylor J, **Brown AW**, Khangoora V; Ahmad K, King CS, Nathan SD. Idiopathic pulmonary fibrosis patients with severe physiologic deficits: characteristics and outcomes. Accepted to ATS 2020.
7. Pastre J, Inga K, Taylor J, **Brown AW**, Aryal S, King CS, Nathan SD. IPF clinical trial PFT entry criteria: How low can we go? ATS 2020.
8. Pastre J, Barnett SD, Ksovreli I, **Brown AW**, Shlobin OA, Ahmad K, Aryal S, Khangoora V, King CS, Nathan SD. Development and Validation Of A Clinical Diagnostic Score System For The Diagnosis Of IPF In Patients with Interstitial Lung Disease. ATS 2020.
9. McLaughlin J, Malik O, **Brown AW**, King CS, Aryal S. A Case Series of HeRO associated Thromboembolic Event. ATS 2020.
10. Kollipara V, Katugaha S, **Brown AW**, King CS. Capnocytophaga sputigena: An Unusual Cause of Bronchiectasis Flare. ATS 2020.
11. Ponor I, Levine D, Cochrane A, Philogene MC, Shah PD, Mathew J, **Brown AW**, Timofte I, Fideli U, Kong H, Marishta A, Yang Y, Tunc I, Luikart H, Berry G, Marboe C, Iacono A, Nathan S, Khush KK, Orens J, Jang M, Valentine H, Agbor-Enoh S. Lung Transplantation: DSA to AMR Trajectory. *J Heart Lung Transplant*. 2020;39(4S).
12. Agbor-Enoh S, Ponor I, Shah P, Levine D, Cochrane A, Philogene M, Matthews J, **Brown AW**, Timofte I, Fideli U, Kong H, Marishta A, Bhatti K, Tunc I, Yang Y, Luikart H, Marboe C, Berry G, Iacono A, Nathan S, Khush KK, Orens J, Jang M, Valentine H. To Treat or Not to Treat: DSA Positive Lung Transplant Recipients. *J Heart Lung Transplant*. 2020 Apr;39(4S).
13. Keller MB, Shah P, Bush E, Diamond JM, Matthews J, **Brown AW**, Timofte I, Fideli US, Kong H, Marishta A, Bhatti K, Yang Y, Tunc I, Luikart H, Berry G, Marboe C, Iacono A, Nathan S, Khush KK, Orens J, Jang M, Valentine HA, Agbor-Enoh S. Donor-Derived-Cell-Free DNA to Identify Primary Graft Dysfunction Patients at Risk of Chronic Lung Allograft Dysfunction. *J Heart Lung Transplant*. 2020;39(4S).
14. Agbor-Enoh S, Charya A, Jang M, Luikart H, Shah P, Matthews J, **Brown AW**, Timofte I, Fideli U, Kong H, Bhatti K, Marishta A, Yang Y, Tunc I, Berry G, Marboe C, Iacono A, Nathan S, Khush K, Orens JB, Valentine H. Allograft Injury and Outcomes in African American Lung Transplant Recipients. *J Heart Lung Transplant*. 2020; 39(4), S55-S56.

15. Bazemore K, Permpalung N, Rohly M, Timofte I, **Brown A**, Orens J, Iacono A, Nathan S, Avery R, Valentine H, Agbor-Enoh S, Shah P. Characterization of Respiratory Pathogens in Contemporary Lung Transplant Recipients. *J Heart Lung Transplant*. 2020; 39(4S).
16. Timofte I, Iacono A, Terrin M, Vesselinov R, Bhatti K, Marishta A, Young C, Pervaiz A, Fideli U, Tunc I, Kwesiga DM, Orens J, Shah P, Nathan SD, **Brown AW**, Valentine HA, Agbor-Enoh S. Lung Transplant Recipients with Severe Primary Graft Dysfunction Requiring ECMO Had Similar Donor-Derived Cell-Free DNA Levels and Lung Function as Matched Controls. *J Heart Lung Transplant*. 2020;39(4S).
17. Ahmad K, King CK, Aryal S, Shlobin OA, Nathan SD, Katugaha S, Zorrilla S, Popa S, Marinak L, Ryan L, **Brown AW**. Staged Bilateral Pneumonectomy: A Bridge to Lung Transplantation. Accepted at ISHLT 2020.
18. Venuto DC, Warden JL Jr, Ho D, Bowen M, Azad-Frouz N, Le Q, King CS, Schmidt ME, Stevenson L, **Brown AW**. Initial Pilot Results of a Novel Point of Care, Rapid Test Detecting *Pseudomonas aeruginosa* in Cystic Fibrosis Patients. Presented at NACFC 2019.
19. Bowen M, Duong Q, Russell C, Connors G, Kopelen R, Palczynski K, King C, **Brown AW**. Outcomes and Impact of a CF Specific Pulmonary Rehabilitation Program. Presented at NACFC 2019.
20. **Brown AW**, Peterson J, Cheng J, Nunes Soares FS, Aryal S, Ahmad K, Koslow M, Weir N, Shlobin OA, King C, Nathan SD. Serial Change in the White Blood Cell Count as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis. Presented at ATS 2019.
21. **Brown AW**, Peterson J, Cheng J, Cannon B, King CK, Nathan SD. White Blood Cell Count and Hospitalization as Additive Prognostic Indicators in Idiopathic Pulmonary Fibrosis. Presented at ATS 2019.
22. Stephenson BW; Swierzbinski M; Ahmad K, Shlobin OA; **Brown AW**; Aryal S; Koslow M; King CS. Filgrastim-Induced Acute Respiratory Distress Syndrome. Presented at ATS.
23. King C; Freiheit, E; **Brown AW**; Venuto D; Flaherty K; Nathan SD. Effects of Anticoagulation on Survival in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry. Presented at ATS 2019.
24. Podder S; Rahim H; Verster A; Shlobin O; King C; **Brown AW**; Nathan SD. Complete Blood Count Parameters as Predictor of Outcomes in Patients with Pulmonary Arterial Hypertension. Presented at ATS 2019.
25. Raghu G, van den Blink B, Hamblin MJ, **Brown AW**, Golden JA, Ho LA, Wijisenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer K, Kreuter M, Santin-Janin H, Aubin F, Mulder GH, Gupta R, Richeldi L. Long-term Safety and Efficacy of Recombinant Human Pentraxin-2 in Patients with Idiopathic Pulmonary Fibrosis. Presented at ATS 2019.
26. Taylor-Cousar JL, Jain R, **Brown AW**, Nash EF. Continuation of dual combination CFTR modulators during pregnancy in women with cystic fibrosis. *J Cyst Fibros* 2019; 18:S22.
27. Inflammatory Events Precede Development of *De Novo* DSA after Lung Transplantation. Presented at ISHLT 2019.
28. King C, Aryal S, Cochrane A, **Brown, AW**, Shlobin OA, Ahmad K, Nathan SD, Marinak L, Fregoso M, Chun J, Shah P, Desai S, Katugaha S. Single Center

- Experience with Use of Letermovir for CMV Prophylaxis or Treatment in Thoracic Organ Transplant Recipients. Presented at ISHLT 2019.
29. Kim MK, **Brown AW**, Shlobin OA, King C, Aryal S, Ahmad K, Cochrane A, Marinak L, Katugaha SB. Cryptococcus laurentii Hip Infection after Lung Transplant. Junior Faculty Clinical Case Reports. Presented at ISHLT 2019.
 30. **Brown AW**, Fregoso M, Peterson J, Nayyar M, Cochrane A, Aryal A, Shlobin O, Pluhacek J, Lemma M, King C, Ramaswamy IK, Deeken JF, Nathan SD. The Impact of Pharmacogenomics on Tacrolimus Dosing and Levels Among Lung Transplant Recipients. Oral Presentation at ISHLT 2019.
 31. Ahmad K, Shlobin OA, Aryal S, Nathan SD, King C, **Brown AW**, Katugaha S. Donor-Derived *Strongyloides* Hyperinfection Syndrome in a Lung Transplant Recipient. Junior Faculty Clinical Case Reports. Presented at ISHLT 2019.
 32. Bowen M, Duong Q, Russell C, Lamberti J, Connors G, **Brown W**. Development and Implementation of a CF Specific Outpatient Pulmonary Rehabilitation Program. Presented at NACFC 2018.
 33. Ratwani A, Ahmad K, King CS, Shlobin OA, Weir N, Aryal S, Nathan SD, **Brown AW**. Connective Tissue Disease associated Interstitial Lung Disease and Outcomes after Hospitalization: a Cohort Study. Presented at Chest 2018.
 34. Poreddy M, Nunes FS, Scully A, Nathan SD, **Brown AW**, Ahmad K, King CS, Shlobin OA, Aryal S, Weir N. Gender and BMI Predict Antifibrotic Tolerance in IPF. Presented at ATS 2018.
 35. Chun J, King C, Fregoso M, Marinak L, Shlobin O, Aryal S, Nathan SD, **Brown AW**. Incidence and Impact of Gallbladder Disease after Lung Transplantation. Presented at ATS 2018.
 36. Jose A, King C, Welt E, Shlobin OA, **Brown AW**, Aryal S, Weir N, Nathan SD. Abnormal Exercise Pulmonary Hemodynamics Predict Outcomes in Patients with Lung Disease. Presented at ATS 2018.
 37. Biru N, King CS, Shlobin OA, Aryal S, Nathan SD, Marinak L, Woods C, **Brown AW**, King CS. Rare case of rapidly progressive interstitial lung disease following adult tetanus, diphtheria, and pertussis (Tdap) vaccination. Presented at ATS 2018.
 38. Mabe D, Shlobin OA, Bogar L, Nathan SD, **Brown AW**, Aryal S, Murphy C, King C. ECMO as a Bridge to Initial Medical Therapy in a Patient with Decompensated Pulmonary Arterial Hypertension. Presented at ATS 2018.
 39. Nunes FS, Vester A, **Brown AW**, King CS, Ahmad K, Fregoso M, Aryal S, Nathan SD, Barnett SD, Shlobin OA. Body Mass Index at Listing May Impact Survival After Lung Transplantation. Presented at ATS 2018.
 40. Ewarien B, **Brown AW**, Libre M, Cochrane A, Marinak L, Ghandi B, Shlobin OA, Nathan SD, King CS. Paravertebral Nerve Block For Pain Control Following Lung Transplantation. Presented at ATS 2018.
 41. Cheng JM, Soares F, Cannon B, **Brown AW**, Nathan SD. The White Blood Cell Count as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2018; 197:A2537.
 42. Gersten RA, Cannon B, Bowen M, Davies E, **Brown AW**. Evaluation of Depression and Anxiety and their Influence on Outcomes in Adult Patients with Cystic Fibrosis. Presented at ATS 2018.

43. Shah P, Rohly M, Joshi A, Timofte I, **Brown AW**, Orens J, Iacono A, Nathan SD, Avery R, Agbor-Enoh S, Valantine H. Donor Derived Cell Free DNA is elevated with pathogens that are risk factors for Chronic Lung Allograft Dysfunction. Presented at ISHLT 2018.
44. Agbor-Enoh S, Jackson AM, Berry G, Cochrane AB, Tunc I, Jang M, Bhatti K, Marishta A, Gorham S, Yang Y, Fideli U, Zhu J, Pirooznia M, Grimm D, Luikart H, Shah P, Timofte I, Iacono A, Cao Z, **Brown AW**, Orens J, Marboe C, Nathan SD, Khush K, Valantine H. Antibody-mediated rejection: should we wait for clinical diagnosis? Presented at ISHLT 2018.
45. **Brown AW**, Agbor-Enoh S, Shah P, Timofte I, Orens J, Iacono A, Lemme M, Barnett S, Soares F, Nathan SD, Ahmad K, Valantine H. Role of dd-cfDNA in Predicting Early Post-Operative Course in Lung Transplant Recipients. Presented at ISHLT 2018.
46. Agbor-Enoh S, Cochrane AB, Jackson AM, I. Tunc, P. Shah, Z. Cao, **Brown AW**, Timofte I, Marishta A, Jang M, Gorham S, Yang Y, Fideli U, Iacono A, Nathan SD, Orens J, Valantine H. Is the New ISHLT Criteria for Pulmonary Antibody-Mediated Rejection also a Severity Indicator? Presented at ISHLT 2018.
47. Agbor-Enoh S, Tunc I, Gorham S, Jang M, Fideli U, Marishta A, Zhu J, Pirooznia M, Yang Y, Davis A, Grimm D, Cao Z, Luikart H, Shah P, Timofte I, **Brown AW**, Iacono A, Nathan SD, Orens J, Khush K, Valantine H. Clinically-unrecognized allograft injury is common after lung transplantation. Presented at ISHLT 2018.
48. Ahmad K, **Brown AW**, Shah P, Timofte I, Orens J, Iacono A, Lemme M, Aryal S, Cochrane A, Nathan SD, Agbor-Enoh S, Valantine H. Role of dd-cfDNA in Predicting Early Hospital Readmission in Lung Transplant Recipients. Presented at ISHLT 2018.
49. Jackson AM, Cochrane AB, Nathan SD, **Brown AW**, Shah P, Orens J, Timofte I, Pham SM, Gorham SS, Bhatti K, Marishta A, Jang M, Yang Y, Fideli U, Tunc I, Zhu J, Iacono I, Agbor-Enoh S, Valantine H. Elevated Donor-Derived Cell-Free DNA (ddcfDNA) as an early risk factor for the development and persistence of de novo donor specific HLA antibody. Presented at ISHLT 2018.
50. Bowen MA, Cochrane AB, Albergott-Barnes L, **Brown AW**. Rapid High Dose Vaccine Series: Increasing Immunity to Hepatitis B in Lung Transplant Candidates. *JHLT* 2018;37(4):S113.
51. Jose A, King C, Welt E, Shlobin OA, **Brown AW**, Aryal S, Weir N, Nathan SD. Abnormal Invasive Pulmonary Hemodynamics Predict Outcomes in Exercising Patients. Presented at ISHLT 2018.
52. Nunes FS, King CS, Nathan SD, Fregoso M, Ahmad K, Aryal S, **Brown AW**, Barnett SD, Shlobin OA, Vester A. High Body Mass Index is a Risk Factor for Acute Cellular Rejection in Lung Transplant Recipients. Presented at ISHLT 2018.
53. Alhalabi L, Cho AH, King CS, Garofalo S, Shlobin OA, Lamberti JP, Nathan SD, **Brown AW**. Outcomes of Patients Requiring High Humidity High Flow Nasal Oxygen Cannula in a Tertiary Care Hospital. Presented at ATS 2017.
54. Libre M, King CS, **Brown AW**, Franco-Palacios D, Shlobin OA, Weir N, Nathan SD. Prevalence of Pulmonary Hypertension in Idiopathic NSIP and Effect of Pulmonary Vasodilator Therapy on Outcomes. Presented at ATS 2017.

55. Nunes FS, King CS, Nathan SD, Fregoso M, Ahmad K, Aryal S, **Brown AW**, Barnett SD, Shlobin OA, Vester A. High Body Mass Index is a Risk Factor for Acute Cellular Rejection in Lung Transplant Recipients. Accepted to ISHLT 2018.
56. Siddiqui F, Nathan S, **Brown AW**, King CS. An Intriguing Case of Pulmonary Langerhans Cell Histiocytosis Following Treatment for Chronic Lymphocytic Leukemia. Presented at ATS 2017.
57. Weir N, **Brown AW**, DelaSantina J, King CS, Lewis D, Franco-Palacios D, Nathan SD, Shlobin OA. Transition from PDE-5 Inhibitors to Riociguat in Pulmonary Hypertension. Presented at ATS 2017.
58. Kaur R, King CS, **Brown AW**, Ahmad SA, Shlobin OA, Weir N, Nathan SD. Factors Affecting the Selection of Anti-Fibrotic Therapy for Idiopathic Pulmonary Fibrosis. Presented at ATS 2017.
59. Kaur R, King CS, **Brown AW**, Ahmad SA, Shlobin OA, Weir N, Nathan SD. Real-World Tolerability of Anti-Fibrotic Therapy for Idiopathic Pulmonary Fibrosis. Presented at ATS 2017.
60. Nunes FS, **Brown AW**, King CS, Battle E, Shlobin OA, Nathan SD. Mid-Flow Rates Do Not Predict Mortality in Idiopathic Pulmonary Fibrosis Patients. Presented at ATS 2017.
61. Jose A, King CS, Shlobin OA, **Brown AW**, Weir N, Kiernan J, Cossa N, Nathan SD. Discordance Between Pulmonary Capillary Wedge Pressure and Left Ventricular End-Diastolic Pressure in a Cohort of Patients with Pulmonary Hypertension. Presented at ATS 2017.
62. Jose A, King CS, Shlobin OA, **Brown AW**, Weir N, Kiernan J, Cossa N, Nathan SD. The Left and Right Ventricular End Diastolic Pressure Ratio as a Novel Marker of Disease Severity in a Cohort of Patients with Pulmonary Arterial Hypertension. Presented at ATS 2017.
63. Tsang AK, Shlobin OA, Weir N, King CS, **Brown AW**, Nathan SD. Do Lung Function Tests Predict Response to Therapy in Connective Tissue Disease (CTD)-Associated Pulmonary Hypertension (PH). Presented at ATS 2017.
64. Siddiqui F, King C, Bowen M, Fregoso M, Nathan SD, **Brown AW**. Similar Outcomes of Lung Transplantation Using Increased Risk and Conventional Donor Lungs. Presented at ATS 2017.
65. Nayyar M, Shlobin OA, King C, Fregoso MF, Verster A, Cochrane A, Nathan SD, **Brown AW**. Outcomes of Recipients on Dual compared to Triple Immunosuppression after Lung Transplantation. *J Heart Lung Transpl*, 2017; 36(4):S410.
66. Hudec N, King CS, Fregoso M, **Brown AW**, Shlobin OA, Cochrane AB. Penicillium Species: Prevalence and Impact on Clinical Outcomes Following Lung Transplantation. Presented at ISHLT 2017.
67. Franco Palacios D, **Brown AW**, King CS, Nunes FS, Mahajan A, Khandhar S, Venbrux A, Shlobin OA. Post-Lung Transplant Chylothorax Effectively Treated with Thoracic Duct Embolization. Presented at ISHLT 2017.
68. King CS, **Brown AW**, et al. ECMO as a bridge: Pre- and Post-Lung Transplant Support. ELSO Conference 2016.

69. Nathan S, Stayrook SA, King C, Weir N, Ahmad S, Shlobin OA, **Brown AW**. Residual Volume-Corrected Forced Vital Capacity Change: A More Accurate Indicator of Outcomes in IPF? *Am J Resp Crit Care Med*. 2016; 193: A4996.
70. Magda G, Della-Santina JL, Stayrook SA, Weir N, King C, Ahmad S, Shlobin OA, **Brown AW**, Della-Santina CP, Nathan SD. Prevalence of Basilar Fibrosis on Abdominal Computerized Tomography Imaging. *Am J Resp Crit Care Med*. 2016; 193: A4981.
71. Trimble AT, Laube BL, **Brown AW**, Zema K, Lechtzin N, Wu J, Waltz D, Bennet WD, Donaldson SH. Durable Improvement in Mucociliary Clearance following a Single Dose of Hypertonic Saline in Cystic Fibrosis. Presented at ATS 2016.
72. Cochrane A, LoRusso M, Fregoso M, Bowen M, Nathan SD, **Brown AW**. Hepatitis B Immunity Prior to Lung Transplantation: Three Shots and You're Out? Presented at ISHLT 2016.
73. Weir NA, MD, Shlobin OA, Lewis D, Nathan SD, Ahmad S, King C, **Brown AW**. Parenchymal Lung Disease in PAH Patients Managed with Prostacyclin Agonists. *JHLT* 2016; 35 (4S): S355.
74. Devarajan SR, **Brown AW**. That Which Bends Up": A PCD patient stricken with Chikungunya in the Americas. *Chest*. 2015;148(4_MeetingAbstracts):156A. doi:10.1378/chest.2261095.
75. Dave, KD, King CK, **Brown AW**, Nathan SD. Lung mass associated with Cystic Lung disease – An evasive diagnosis in a patient with Primary Sjögren's. Presented at Chest 2015.
76. Shin S, King C, Puri N, Shlobin AO, **Brown AW**, Nathan SD. Utilization of pulmonary arterial size and coronary artery calcification on HRCT imaging for prognostic stratification in patients with IPF. *Am J Resp Crit Care Med*. 2015; A2513.
77. Raza M, Hostler D, Shlobin OA, **Brown AW**, Ahmad S, Nathan SD. The Incidence of Heart Failure with Preserved Ejection Fraction among Lung Transplant Recipients. *Am J Resp Crit Care Med*. 2015; A1423.
78. King CS, Ahmad S, Valentino V, Shlobin OA, **Brown AW**, Cattamanchi A, Singh R, Nathan SD. An International Survey of Early Post-operative Management Practice Patterns Following Lung Transplantation. *Am J Resp Crit Care Med*. 2015; A1424.
79. Ahmad S, Shafagati N, Shlobin OA, King C, Nathan SD, **Brown AW**. Association of Coagulation Protein Levels in Development of Deep Venous Thrombosis in Lung Transplant Recipients. *Am J Resp Crit Care Med*. 2015; 191:A1426.
80. Kaya H, **Brown AW**, Amdur R, Nathan SD. Distance supplemental oxygen (DSO): An index to predict the survival in IPF. *Am J Resp Crit Care Med* 2015; 191:A5506.
81. Kaya H, Nathan SD, Ahmad S, Shlobin OA, King CS, Weir N, **Brown AW**. 6MWT Distance to Predict the Survival in Pulmonary Hypertension. *Am J Resp Crit Care Med* 2015; 191:A5506.
82. Cohee BM, **Brown AW**, Shlobin OA, Kiernan JM, Mani H, Fregoso M, Germano K, Nathan SD, Ahmad S. Adenovirus Infection Presenting as a Solitary Mass Lesion with Lymphocytic Effusion in a Lung Transplant Recipient. Presented at Chest 2014.

83. Hong A, Khandhar S, **Brown AW**, Bogar L, Ahmad S, Shlobin OA, King C, Burton NA, Nathan SD. Hemothorax after Lung Transplantation. *Amer J Resp Crit Care Med* 2014; A1593.
84. Buhr RG, Shlobin OA, **Brown AW**, Ahmad S, Weir NA, Nathan SD. Six minute walk test pulse rate recovery as a predictor of pulmonary hypertension in COPD. Presented at Chest 2013.
85. Buhr RG, Shlobin OA, **Brown AW**, Ahmad S, Weir NA, Nathan SD. Treatment of pulmonary hypertension in COPD: implications for exercise tolerance and mortality. Presented at ATS 2013.
86. Fischer C, **Brown AW**, Shlobin OA, Ahmad S, Weir N, Nathan SD. Hospitalization of IPF patients as a clinical trial endpoint: what are the long-term implications? Presented at ATS 2013.
87. Shin S, **Brown AW**, Ahmad S, Newton K, Weir W, Shlobin OA, Nathan SD. Relationship between pulmonary arterial size on CT imaging and pulmonary artery pressures in patients with COPD. Presented at ATS 2013.
88. Shin S, **Brown AW**, Ahmad S, Newton K, Weir W, Shlobin OA, Nathan SD. Pulmonary arterial size on CT imaging as a predictor of outcomes in patients with COPD. Presented at ATS 2013.
89. Ahmad S, **Brown AW**, Shlobin OA, Burton NA, Nathan SD. Effect of Age on Outcomes after Lung Re-Transplantation. Presented at ATS 2013.
90. Weir N, Smith M, Reffett T, Battle E, Shlobin OA, **Brown AW**, Ahmad S, Nathan SD. The 6MWT: How Far or How Fast? Presented at ATS 2012.
91. Nathan SD, Ahmad S, Ahmed S, **Brown AW**, Shlobin OA, Weir N, Arcasoy S, Barnett S, Lederer D. An Unexpected Association Between Ambient Air Pollution and Survival Time in IPF. Presented at ATS 2012.
92. Mazer A, M. Fregoso M, Ahmad S, **Brown AW**, Shlobin O, Weir N, Nathan S. Relationship Between Red Cell Distribution Width And Mortality After Lung Transplantation. Presented at Chest 2012.
93. Hostler J, **Brown AW**, Ahmad S, Nathan S, Shlobin OA. Primary Central Nervous System Lymphoma: A Rare Post Lung Transplantation Lymphoproliferative Disorder. Presented at Chest 2012.
94. Nathan SD, Reffett TR, **Brown AW**, Shlobin OA, Ahmad S, Weir N, Sheridan MJ. The Red Cell Distribution Width as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis. Presented at ATS 2012.
95. Fleury C, Shlobin OA, **Brown AW**, Ahmad S, McGehee H, Nathan SD. Impact of the Lung Allocation Score System on Lung Transplantation for Sarcoidosis. Presented at ATS 2012.
96. Nathan SD, **Brown AW**, Albano MC, Shlobin OA, Ahmad S, Smith M, Weir N, Leslie K. The Temporal Attenuation of IPF Mortality: An Analysis of Five Year Survivors. Presented at ATS 2012.
97. Weir N, Smith M, Reffett T, Battle E, Shlobin OA, **Brown AW**, Ahmad S, Nathan SD. The 6MWT: How far or how fast? Presented at ATS 2012
98. Collen J, Shlobin OA, **Brown AW**, Weir N, Nathan SD, Ahmad S. Congenital absence of one pulmonary artery: An Uncommon Cause of Pulmonary Hypertension (case report). Presented at Chest 2011.

99. Collen J, Fregoso MM, Brenner RL, Reffett T, **Brown AW**, Shlobin OA, Ahmad S, Lemma M, Nathan SD. Do CT findings correlate with the phenomena of “BOS” and “DeBOS/ReBOS” in lung transplant patients? Presented at Chest 2011.
100. Kilaru S, **Brown AW**, Shlobin OA, Ahmad A, Weir N, Fregoso M, Athale C, Burton NA, Nathan SD. Utility of Immune Cell Function Assay Monitoring in Lung Transplant Recipients. *Am J Respir Crit Care Med* 183;2011:A1149.
101. Ahmad SA, Bukhary ZA, Shlobin OA, **Brown AW**, Schmidt M, Nathan SD. Incidence and Outcome of Nontuberculous Mycobacterial Infection after Lung Transplantation. *Am J Respir Crit Care Med* 183;2011:A4647.
102. Obi IA, **Brown AW**, Shlobin OA, Ahmad S, Weir N, Fregoso M, Athale C, Burton NA, Nathan SD. Montelukast for the Treatment of BOS Post-Lung Transplantation. *Am J Respir Crit Care Med* 183;2011:A1137.
103. Mazer A, Shlobin OA, Weir N, **Brown AW**, Ahmad S, Barnett SD, Nathan SD. Hemodynamic Predictors of Functional Ability in Patients with Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* 183;2011:A1519.
104. Fregoso MM, Brenner RL, Collen J, Reffett T, **Brown AW**, Shlobin OA, Ahmad S, Lemma M, Nathan SD. BOS, “DeBos” and “ReBos”: When is a drop in the FEV1 really permanent? *J Heart Lung Transplant* 2011; 30:4S:S53.
105. Shlobin OA, **Brown AW**, Weir N, Lemme M, , Brown K, Ahmad S, Nathan SD. Sildenafil to Tadalafil Transition in Patients with Pulmonary Arterial Hypertension: A Retrospective Review. *J Heart Lung Transplant* 2011;30:4S:S7.
106. **Brown AW**, Laube BL, Zeman K, Lechtzin N, Sharpless G, Wu J, Donaldson S, Bennett WD. Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis. Proceedings of the North American Cystic Fibrosis Foundation Conference, Supplement to Pediatric Pulmonology, 2010.
107. Donaldson SH, Bendahmane N, Zeman K, Wu J, **Brown AW**, Hill DB, Boucher RC, Bennett WD. A Double Blind Cross-Over Study Comparing Aerosolized Lucinactant and Vehicle on Mucociliary Clearance for CF Lung Disease. Proceedings of the North American Cystic Fibrosis Foundation Conference, Supplement to Pediatric Pulmonology, 2010.
108. Formeister EJ, **Brown AW**, Bills LB, Amann K, Hohneker KW, Donaldson SH. Feasibility and Efficacy of a Home Spirometry Quality Improvement Program in Adult Cystic Fibrosis Patients. Proceedings of the North American Cystic Fibrosis Foundation Conference, Supplement to Pediatric Pulmonology, 2010.
109. **Brown AW**, Esther CR, Hohneker K, Gilligan PH, Coakley R. *Achromobacter* (Alcaligenes) Xylosoxidans is associated with Increased Rate of Lung Function Decline in Cystic Fibrosis. Proceedings of the North American Cystic Fibrosis Foundation Conference, Supplement to Pediatric Pulmonology, 2008.
110. Hatcher CJ, **Brown AW**, Diman NY, Basson CT. Identification of a novel downstream target for TBX5 regulation of cardiac development. *Circ* 2006; 114(18): Suppl. II-195.

TALKS/PRESENTATIONS AT INTERNATIONAL MEETINGS

2021 ATS, Moderator: Thematic Poster Session: Epidemiology, Biomarkers, and Therapy in CF and non-CF Bronchiectasis

2020 ISHLT, Speaker: Symposium on Building on a Solid Foundation: Guidelines and Unique Challenges in CF Lung Transplant

2018 ATS, Facilitator: Poster Session on Outcomes in ILD

2017 ATS, Moderator: Lung Transplantation Abstract Session

2016 ATS, Moderator: Predictors of Outcome in Interstitial Lung Disease Abstract Session

2016 ISHLT, Poster Presentation: Hepatitis B Immunity Prior to Lung Transplantation

2015 ISHLT, Symposium Speaker: Special Considerations for Lung Transplantation in Cystic Fibrosis

2011 North American Cystic Fibrosis Conference, Moderator

2009 North American Cystic Fibrosis Conference, Workshop Speaker

2008 North American Cystic Fibrosis Conference, Adult Fellow Case Symposium Presenter

MULTICENTER STUDIES

1. Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility, 2019-ongoing **(Site PI)**.
2. A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis, 2019-2021 **(Site PI)**.
3. VX 445/TEZ/IVA Triple Combination Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function CFTR Mutation, 2019-2020 **(Site PI)**.
4. A Phase 2, Multicenter, Open-label Study to Measure the Safety of Extending Preservation and Assessment Time of Donor Lungs Using Normothermic Ex Vivo Lung Perfusion and Ventilation (EVLP) as Administered by the SPONSOR Using the Toronto EVLP System, 2018-2019 **(Site PI)**.
5. A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis, 2016-2019 **(Site PI)**.
6. Genome Transplant Dynamics: NHLBI Sponsored Multicenter, Prospective Cohort Study of Circulating Cell-free Donor-Derived DNA of Heart and Lung Transplant Patients Recruited Through a Transplant Consortium, 2015-ongoing **(Site PI)**.
7. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With

Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension, 2014-2016 (Site PI).

8. **A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection, 2011-2013 (Site PI).**